Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixarelimab in Moderate to Severe Active Ulcerative Colitis
NCT06693908Phase 1Completed
- Sponsor
- Genentech
- Start
- Mar 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vixarelimab in ulcerative colitis (UC), sponsored by Genentech. Primary endpoint: Change From Baseline in Fibroblast Products From Colonic Tissue at 3 months. Started Mar 2025; status: completed.
02
Drugs
vixarelimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06693908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693908.